According to our new research study on “The global Molecular Quality Controls Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Application, Analyte Type and End User,” the market is expected to reach US$ 372.64 million in 2028 from US$ 184.62 million in 2021; it is estimated to grow at a CAGR of 10.6% during 2021–2028. The report highlights trends prevailing in the market and factors driving its growth. The growth of the molecular quality controls market is mainly attributed to the factors such as growing funds for genomics, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
Based on application, the molecular quality controls market is segmented into infectious diseases, oncology, genetic testing, and other applications. The infectious diseases segment held the largest share of the market in 2020, whereas the oncology segment is anticipated to register the highest CAGR in the market during the forecast period. Infectious diseases segment is expected to capture significant market share owing to high incidences of infectious disease outbreaks all over the world, technological advancements in molecular diagnostic testing and product developments by the market players. For instance, in 2018, Microbiologics Inc. launched 8 quality control products: Human Papillomavirus (HPV) Control Panel, Vaginal infection Control Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.
The leading companies operating in the molecular quality controls market are Thermo Fisher Scientific Inc; Bio-Rad Laboratories Inc; F. Hoffmann la-Roche Ltd; Abbott; Quidel Corporation; Qnostics; Maine Molecular Controls Inc; Zeptometrix Corporation; Microbiologics, and Seracare Life Sciences.
Increasing Prevalence of Genetic Diseases
Molecular quality controls are used to detect genetic diseases as these aid in the interpretation of results. Downs Syndrome is a genetic disorder that causes due to abnormal cell division, which results in an extra full or partial copy of chromosome 21. As per the US Centers for Disease Control and Prevention (CDC), every year, around 6,000 newborns in the US suffer from the Down syndrome. As a result, prenatal testing for Down syndrome is increasing in the country.
Get a Sample Copy of the Report@ https://www.theinsightpartners.com/sample/TIPRE00005166/
Most of the inherited cases of breast cancer are associated with mutations in two genes: BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two). As per the American Cancer Society, around 5% to 10% of breast cancer cases are hereditary, as a result of mutated genes passed from parent to children. Growing awareness of breast cancer increases the adoption of genetic testing for hereditary breast cancer.
Further, as per CDC, sickle cell disease (SCD) is a common genetic blood disorder in the US that affects ~70,000 to 100,000 Americans. Further, as per the WHO, 5% of the world population is the carrier of the genes for hemoglobin disorders, such as sickle-cell disease and thalassemia. Thus, the increasing prevalence of such genetic diseases propels the demand for molecular quality controls.
Based on product, the molecular quality controls market is segmented into independent controls and instrument specific controls. The independent controls segment held a larger share of the market in 2020, whereas the same is anticipated to register the highest CAGR in the market during the forecast period.
Based on analyte type, the molecular quality controls market is segmented into single analyte controls and multi-analyte controls. The single analyte controls segment held a larger share of the market in 2021, whereas the multi-analyte control segment is estimated to register the highest CAGR in the market during the forecast period.
Based on application, the molecular quality control market is segmented into infectious diseases, oncology, genetic testing, and other applications. The infectious diseases segment held the largest share of the market in 2021, whereas the oncology segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on end user, the molecular quality control market is segmented into clinical laboratories, hospitals, IVD manufacturers & contract research organizations, academic & research institutes, and other end users. The Clinical Laboratories segment held the largest share of the market in 2021 and is estimated to register the highest CAGR of in the market during the forecast period.
About The Insight Partners
The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as healthcare, media, and telecommunication.
Our research model is very simple. We Believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.
Our research content is majorly focused on market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, systems, products, and services, etc., which helps our clients to gain a deeper analytical understanding of various research topics.
Contact Us
If you have any queries about this report or if you would like further information, please contact us:
North America: +1 646 491 9876
Asia Pacific: +91 20 6727 8686
Email: info@theinsightpartners.com